Literature DB >> 16756719

Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer.

Joseph Kwong1, Ji-Young Lee, Kwong-Kwok Wong, Xiaofeng Zhou, David T W Wong, Kwok-Wai Lo, William R Welch, Ross S Berkowitz, Samuel C Mok.   

Abstract

Suppression of ovarian tumor growth by chromosome 3p was demonstrated in a previous study. Deleted in Lung and Esophageal Cancer 1 (DLEC1) on 3p22.3 is a candidate tumor suppressor in lung, esophageal, and renal cancers. The potential involvement of DLEC1 in epithelial ovarian cancer remains unknown. In the present study, DLEC1 downregulation was found in ovarian cancer cell lines and primary ovarian tumors. Focus-expressed DLEC1 in two ovarian cancer cell lines resulted in 41% to 52% inhibition of colony formation. No chromosomal loss of chromosome 3p22.3 in any ovarian cancer cell line or tissue was found. Promoter hypermethylation of DLEC1 was detected in ovarian cancer cell lines with reduced DLEC1 transcripts, whereas methylation was not detected in normal ovarian epithelium and DLEC1-expressing ovarian cancer cell lines. Treatment with demethylating agent enhanced DLEC1 expression in 90% (9 of 10) of ovarian cancer cell lines. DLEC1 promoter methylation was examined in 13 high-grade ovarian tumor tissues with DLEC1 downregulation, in which 54% of the tumors showed DLEC1 methylation. In addition, 80% of ovarian cancer cell lines significantly upregulated DLEC1 transcripts after histone deacetylase inhibitor treatment. Therefore, our results suggested that DLEC1 suppressed the growth of ovarian cancer cells and that its downregulation was closely associated with promoter hypermethylation and histone hypoacetylation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16756719      PMCID: PMC1600675          DOI: 10.1593/neo.05502

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  33 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas.

Authors:  J H Yoon; R Dammann; G P Pfeifer
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

Review 3.  Genetic susceptibility to breast and ovarian cancer.

Authors:  M H Skolnick; T Frank; D Shattuck-Eidens; S Tavtigian
Journal:  Pathol Biol (Paris)       Date:  1997-03

4.  Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis.

Authors:  Noriyuki Takai; Norihiko Kawamata; Dorina Gui; Jonathan W Said; Isao Miyakawa; H Phillip Koeffler
Journal:  Cancer       Date:  2004-12-15       Impact factor: 6.860

Review 5.  Hereditary and sporadic ovarian cancer: genetic testing and clinical implications (review).

Authors:  R Angioli; R Estape; M Mason; M Penalver
Journal:  Int J Oncol       Date:  1998-05       Impact factor: 5.650

6.  Deletion mapping using quantitative real-time PCR identifies two distinct 3p21.3 regions affected in most cervical carcinomas.

Authors:  Vera Senchenko; Jian Liu; Eleonora Braga; Natalia Mazurenko; Witaly Loginov; Yury Seryogin; Igor Bazov; Alexei Protopopov; Fedor L Kisseljov; Vladimir Kashuba; Michael I Lerman; George Klein; Eugene R Zabarovsky
Journal:  Oncogene       Date:  2003-05-15       Impact factor: 9.867

7.  Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas.

Authors:  Vera N Senchenko; Jian Liu; Witaly Loginov; Igor Bazov; Debora Angeloni; Yury Seryogin; Valeria Ermilova; Tatiana Kazubskaya; Raisa Garkavtseva; Veronika I Zabarovska; Vladimir I Kashuba; Lev L Kisselev; John D Minna; Michael I Lerman; George Klein; Eleonora A Braga; Eugene R Zabarovsky
Journal:  Oncogene       Date:  2004-07-29       Impact factor: 9.867

8.  Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients.

Authors:  Inmaculada Ibanez de Caceres; Cristina Battagli; Manel Esteller; James G Herman; Essel Dulaimi; Mitchell I Edelson; Cynthia Bergman; Hormoz Ehya; Burton L Eisenberg; Paul Cairns
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

9.  Mapping of chromosome 3p deletions in human epithelial ovarian tumors.

Authors:  H Lounis; A M Mes-Masson; F Dion; W E Bradley; R J Seymour; D Provencher; P N Tonin
Journal:  Oncogene       Date:  1998-11-05       Impact factor: 9.867

10.  Epigenetic inactivation of TMS1/ASC in ovarian cancer.

Authors:  Katsuhiko Terasawa; Satoru Sagae; Minoru Toyota; Kuniko Tsukada; Kazuhiro Ogi; Ayumi Satoh; Hiroaki Mita; Kohzoh Imai; Takashi Tokino; Ryuichi Kudo
Journal:  Clin Cancer Res       Date:  2004-03-15       Impact factor: 12.531

View more
  32 in total

1.  DLEC1, a 3p tumor suppressor, represses NF-κB signaling and is methylated in prostate cancer.

Authors:  Lian Zhang; Qian Zhang; LiLi Li; Zhaohui Wang; Jianming Ying; Yu Fan; Qun He; Tianjing Lv; Wenke Han; Jun Li; Yang Yang; Ben Xu; Lu Wang; Qianling Liu; Yinghao Sun; Yinglu Guo; Qian Tao; Jie Jin
Journal:  J Mol Med (Berl)       Date:  2015-02-05       Impact factor: 4.599

2.  Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells.

Authors:  Juan Wang; Jun-Ying Zhou; Lianfeng Zhang; Gen Sheng Wu
Journal:  Cell Cycle       Date:  2009-10-07       Impact factor: 4.534

3.  CDKN2B, SLC19A3 and DLEC1 promoter methylation alterations in the bone marrow of patients with acute myeloid leukemia during chemotherapy.

Authors:  Qingxiao Hong; Yirun Li; Xiaoying Chen; Huadan Ye; Linlin Tang; Annan Zhou; Yan Hu; Yuting Gao; Rongrong Chen; Yongming Xia; Shiwei Duan
Journal:  Exp Ther Med       Date:  2016-02-19       Impact factor: 2.447

4.  Aberrant promoter methylation of SPARC in ovarian cancer.

Authors:  Matthew J Socha; Neveen Said; Yanshan Dai; Joseph Kwong; Preetha Ramalingam; Vuong Trieu; Neil Desai; Samuel C Mok; Kouros Motamed
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

5.  Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer.

Authors:  Takako Kawasaki; Katsuhiko Nosho; Mutsuko Ohnishi; Yuko Suemoto; Gregory J Kirkner; Reiko Dehari; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

6.  Curcumin inhibits anchorage-independent growth of HT29 human colon cancer cells by targeting epigenetic restoration of the tumor suppressor gene DLEC1.

Authors:  Yue Guo; Limin Shu; Chengyue Zhang; Zheng-Yuan Su; Ah-Ng Tony Kong
Journal:  Biochem Pharmacol       Date:  2015-01-29       Impact factor: 5.858

7.  Role for DUSP1 (dual-specificity protein phosphatase 1) in the regulation of autophagy.

Authors:  Juan Wang; Jun-Ying Zhou; Dhonghyo Kho; John J Reiners; Gen Sheng Wu
Journal:  Autophagy       Date:  2016-07-26       Impact factor: 16.016

8.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

9.  Methylation of the DLEC1 gene correlates with poor prognosis in Japanese lung cancer patients.

Authors:  Hidefumi Sasaki; Yu Hikosaka; Osamu Kawano; Satoru Moriyama; Motoki Yano; Yoshitaka Fujii
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

10.  Gene methylation profiles as prognostic markers in ovarian clear cell and endometrioid adenocarcinomas.

Authors:  Chi-An Chen; Ying-Cheng Chiang; Ming-Cheng Chang; Yu-Hao Hu; San-Lin You; Yeu-Yao Kevin Cheng; Cheng-Yang Chou; Wen-Fang Cheng
Journal:  Am J Transl Res       Date:  2015-01-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.